Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas
Summary: BRCA1/2-mutated ovarian cancers (OCs) are defective in homologous recombination repair (HRR) of double-strand breaks (DSBs) and thereby sensitive to platinum and PARP inhibitors (PARPis). Multiple PARPis have recently received US Food and Drug Administration (FDA) approval for treatment of...
Main Authors: | Khyati Meghani, Walker Fuchs, Alexandre Detappe, Pascal Drané, Ewa Gogola, Sven Rottenberg, Jos Jonkers, Ursula Matulonis, Elizabeth M. Swisher, Panagiotis A. Konstantinopoulos, Dipanjan Chowdhury |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-04-01
|
Series: | Cell Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124718303802 |
Similar Items
-
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer
by: Young Eun Choi, et al.
Published: (2016-01-01) -
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
by: Liya Ding, et al.
Published: (2018-12-01) -
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential
by: Tarra Evans, et al.
Published: (2017-04-01) -
Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers.
by: Kimiyo N Yamamoto, et al.
Published: (2014-01-01) -
Current status and evolution of preclinical drug development models of epithelial ovarian cancer
by: Panagiotis A Konstantinopoulos, et al.
Published: (2013-12-01)